18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: The time period during which PET/CT can reliably detect non-recurrence

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 7, 2010, Pages 1318-1327

  Ito, Kimiteru ^a   Yokoyama, Jyunkichi ^b   Kubota, Kazuo ^c   Morooka, Miyako ^c   Shiibashi, Michio ^a   Matsuda, Hiroshi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b TOCHIGI CANCER CENTER   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Choline; FDG; Head and neck cancer; PET CT; Recurrence

Indexed keywords

CHOLINE C 11; CISPLATIN; FLUORODEOXYGLUCOSE F 18; CARBON; CHOLINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG UPTAKE; FEMALE; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; COMPARATIVE STUDY; FOLLOW UP; HEAD AND NECK TUMOR; INTRAARTERIAL DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE; REPRODUCIBILITY; TIME; TREATMENT OUTCOME;

AGED; CARBON RADIOISOTOPES; CHOLINE; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77954960135     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1400-x     Document Type: Article

References (34)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
2. Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51:571-8.
3. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994;73:187-90.
4. Hass I, Hauser U, Ganzer U. The dilemma of follow-up in head and neck cancer patients. Eur Arch Otorhinolaryngol 2001;258:177-83.
5. Takayama O, Yokoyama J, Ito S. Therapeutic experience of recurrent myoepithelial carcinoma by superselective intra-arterial chemotherapy infused high-dose CDDP. Auris Nasus Larynx 2006;33:235-8.
6. Homma A, Furuta Y, Suzuki F, Oridate N, Hatakeyama H, Nagahashi T, et al. Rapid superselective high-dose cisplatin infusion with concomitant radiotherapy for advanced head and neck cancer. Head Neck 2005;27:65-71.
7. Ong SC, Schöder H, Lee NY, Patel SG, Carlson D, Fury M, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008;49:532-40.
8. Wong RJ, Lin DT, Schöder H, Patel SG, Gonen M, Wolden S, et al. Diagnostic and prognostic value of [(18) F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002;20:4199-208.
9. Abgral R, Querellou S, Potard G, Le Roux PY, Le Duc-Pennec A, Marianovski R, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009;50:24-9.
10. Fakhry N, Lussato D, Jacob T, Giorgi R, Giovanni A, Zanaret M. Comparison between PET and PET/CT in recurrent head and neck cancer and clinical implications. Eur Arch Otorhinolaryngol 2007;264:531-8.
11. Kubota K, Yokoyama J, Yamaguchi K, Ono S, Qureshy A, Itoh M, et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging 2004;31:590-5.
12. Kitagawa Y, Sano K, Nishizawa S, Nakamura M, Ogasawara T, Sadato N, et al. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging 2003;30:63-71.
13. Döbert N, Kovács AF, Menzel C, Engels K, Kranert WT, Grünwald F. FDG uptake after intraarterial chemotherapy in head and neck cancer. Nuklearmediz 2006;45:243-7.
14. Kitagawa Y, Sadato N, Azuma H, Ogasawara T, Yoshida M, Ishii Y, et al. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. J Nucl Med 1999;40:1132-7.
15. Khan N, Oriuchi N, Ninomiya H, Higuchi T, Kamada H, Endo K. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET. Ann Nucl Med 2004;18:409-17.
16. Ninomiya H, Oriuchi N, Kahn N, Higuchi T, Endo K, Takahashi K, et al. Diagnosis of tumor in the nasal cavity and paranasal sinuses with [11C]choline PET: comparative study with 2-[18F] fluoro-2-deoxy-D-glucose (FDG) PET. Ann Nucl Med 2004;18:29-34.
17. Tian M, Zhang H, Oriuchi N, Higuchi T, Endo K. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging 2004;31:1064-72.
18. Shinoura N, Nishijima M, Hara T, Haisa T, Yamamoto H, Fujii K, et al. Brain tumors: detection with C-11 choline PET. Radiology 1997;202:497-503.
19. Hara T, Kosaka N, Suzuki T, Kudo K, Niino H. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest 2003;124:893-901.
20. Kubota K. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001;15:471-86.
21. Roivainen A, Forsback S, Grönroos T, Lehikoinen P, Kähkönen M, Sutinen E, et al. Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000;27:25-32.
22. Aiken NR, Gillies RJ. Phosphomonoester metabolism as a function of cell proliferative status and exogenous precursors. Anticancer Res 1996;16:1393-8.
23. Warden CH, Friedkin M. Regulation of choline kinase activity and phosphatidylcholine biosynthesis by mitogenic growth factors in 3T3 fibroblasts. J Biol Chem 1985;260:6006-11.
24. Macara IG. Elevated phosphocholine concentration in ras-transformed NIH 3T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown. Mol Cell Biol 1989;9:325-8.
25. Teegarden D, Taparowwsky EJ, Kent C. Altered phosphatidylcholine metabolism in C3H10T [1/2] cells transfected with the Harvey-ras oncogene. J Biol Chem 1990;265:6042-7.
26. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancers, V.2.2008. Available at: http://www.nccn. Org/professionals/physician-gls/PDF/head-and-neckpdf. Accessed 20 Nov. 2008.
27. Hara T. 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol 2002;4:267-73.
28. Henriksson E, Kjellen E, Baldetorp B, Bendahl PO, Borg A, Brun A, et al. Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck. J Exp Clin Cancer Res 2009;28:17.
29. Lee M, Baum U, Greess H, Nömayr A, Nkenke E, Koester M, et al. Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI. Eur J Radiol 2000;33:239-47.
30. Lapela M, Eigtved A, Jyrkkiö S, Kurki T, Lindholm P, Nuutinen J, et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 2000;36:858-67.
31. Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000;110:1493-7.
32. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 1999;213:521-5.
33. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995;36:1836-9.
34. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-900.